Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05160220
Other study ID # 001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 20, 2021
Est. completion date October 1, 2021

Study information

Verified date December 2021
Source National Council of Scientific and Technical Research, Argentina
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study seeks to understand the neural, cognitive and behavioral effects of low doses of psilocybin administered in the form of dried mushroom material (0.5 g of Psilocybe cubensis) consumed in natural settings following a placebo-controlled double-blind experimental design.


Description:

Sub-threshold doses of serotonergic psychedelics are frequently consumed as cognitive enhancers, and due to their purported positive effects on mood, energy and creativity ("microdosing"). The acute and short-term effects of psilocybin (the psychoactive compound of Psilocybe cubensis mushrooms) on several variables will be investigated, comprising spontaneous and evoked electrophysiological brain activity, perception and cognitive function (cognitive flexibility, attention, inhibitory control, conscious access, visual perception), creativity (problem solving, divergent and convergent thinking), behavior (actigraphy and sleep patterns, natural language production) and several domains related to well-being and mental health of the participants. This study is simultaneously naturalistic (i.e. recruited subjects are intrinsically motivated to microdose, as they have decided to embark in a microdosing protocol) and controlled by expectations, following a double-blind placebo-controlled design. Participants will microdose according to the following schedule: Two sessions (0.5 g dried Psilocybin mushrooms vs. dried edible mushroom material without psychoactive effects as a placebo condition) will be conducted. A third party will be in charge of generating their active dose and placebo capsules, and they will also implement a blinding procedure. Each session will span one week of measurements. Subjects will be given a smartwatch to monitor activity and sleeping patterns at the beginning of the week. At days 3 and 5, subjects will take capsules with active mushroom material or placebo, and then several variables will be recorded. Experiments will be conducted in a setting that is natural and comfortable for the participants, e.g. their homes. The main outcome measures consist of resting state activity recorded with EEG, evoked response potentials and performance during cognitive tasks, behavioral variables obtained with actigraphy and automated sleep scoring, natural language analysis, and several measurs self-reported via standarized questionnaires. After completion, this study will provide direct evidence concerning the efficacy of microdosing for cognitive enhancement under natural conditions, i.e. those most frequently used by individuals who microdose, as well as provide information concerning the potential underlying neurobiological mechanisms.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date October 1, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: 1. Men and woman with more than 21 years. 2. Participans are planning to microdose using their own dried mushroom material and adhere to the experimental protocol. 3. No active psychiatric conditions requiring treatment with psychotropic medications. 4. Able to provide informed consent. Excusion Criteria: 1. Use of psychotropic medication during the study, including stimulants such as caffeine. 2. Prior adverse reactions to psychedelics according to the Challenging Experiences Questionnaire administered during initial screening. 3. Pregnant women or women during lactation 4. History of high or low blood pressure or other cardiovascular risks.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Psilocybin
0.5 g dried Psilocybe cubensis mushroom material, 0.8 mg psilocybin.
Placebo
0.5 g dried edible non-psychoactive mushroom material.

Locations

Country Name City State
Argentina Instituto de Fisica de Buenos Aires (IFIBA) Buenos Aires

Sponsors (1)

Lead Sponsor Collaborator
National Council of Scientific and Technical Research, Argentina

Country where clinical trial is conducted

Argentina, 

Outcome

Type Measure Description Time frame Safety issue
Primary Resting state oscillations measured with EEG Our goal is to study changes in spectral content before and during the acute effects with the purpose of comparing changes with those observed under higher doses of psilocybin. 1 week
Primary Attention Measured performance in the attentional blink paradigm 1 week
Primary Inhibitory control Measured using the go/no go experimental paradigm 1 week
Primary Conscious access Measured using the backward masking paradigm 1 week
Primary Visual perception Measured using the binocular rivalry paradigm 1 week
Primary Physical activity Measured using wrist actigraphy using a smartwach 1 week
Primary Divergent thinking Measured using the Alternative Uses Task (AUT) 1 week
Primary Attention Measured using the hiearchical mismatch negativity paradigm combined with EEG 1 week
Primary Cognitive flexibility Measured using the stroop task 1 week
Primary Convergent thinking Measured using the Remote Associations Task (RAT) 1 week
Primary Convergent thinking Measured using the Wallach-Kogan test (WK) 1 week
Secondary Effect positive/negative affect and well-being Measured using the Positive and Negative Affect Schedule (PANAS) 1 week
Secondary Effects on anxiety Measured using State Trait Anxiety Inventory (STAI) 1 week
Secondary Effects on personality Measured using the Big Five inventory (BFI) 1 week
Secondary Concentration of psilocybin in the dried material To be measured using high performance liquid chromatography 1 week
See also
  Status Clinical Trial Phase
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Recruiting NCT06079853 - Nurse Suicide: Physiologic Sleep Health Promotion Trial N/A
Completed NCT05017974 - Research on Improving Sleep During Pregnancy N/A
Recruiting NCT05206747 - Ottawa Sunglasses at Night for Mania Study N/A
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT04513743 - Ultra Long-Term Sleep Monitoring Using UNEEG™ Medical 24/7 EEG™ SubQ N/A
Completed NCT03251274 - Bath Machine on Sleep Quality in Nursing Home N/A
Completed NCT04102345 - Lavender vs Zolpidem Sleep Quality During Diagnostic PSG Early Phase 1
Completed NCT03725943 - Comparison of Dreem to Clinical PSG for Sleep Monitoring in Healthy Adults N/A
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Completed NCT04562181 - Consistency Evaluation of the qCON, qNOX Indices and Bispectral Index N/A
Completed NCT05102565 - A Dyadic Telehealth Program for Alzheimer's Patients/Caregivers N/A
Completed NCT05576844 - Ai Youmian (Love Better Sleep) for People Living With HIV N/A
Completed NCT04688099 - Synovial Fluid Sleep Study
Recruiting NCT04171245 - Prescribing Laughter for Sleep and Wellbeing in UAE University Students N/A
Completed NCT03758768 - The Effects of a Blue Monochromatic Light Intervention on Evening-type Individuals' Sleep and Circadian Rhythms N/A
Completed NCT03163498 - Evaluation of Sleep Pattern and Mood Profile in Hypertensive Patients
Completed NCT04093271 - Investigating the Efficacy of Rest-ZZZ Formula in Healthy Participants With Difficulty Falling Asleep or Staying a Sleep Phase 1
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Completed NCT04120363 - Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations Phase 4